期刊文献+

PT-Cy方案联合芦可替尼及托珠单抗预防单倍型相合造血干细胞移植后aGVHD的效果 被引量:1

PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT
下载PDF
导出
摘要 目的采用单臂前瞻性研究评估PT-Cy(post-transplant cyclophosphamide)方案联合芦可替尼、托珠单抗预防单倍型相合异基因外周血造血干细胞移植(hematopoietic stem cell transplantation,HSCT)后急性移植物抗宿主病(acute graft versus host disease,aGVHD)的疗效。方法收集2019年1月1日至2020年3月1日本院血液科行单倍型相合异基因外周血HSCT的56例患者资料。预防aGHVD方案:环磷酰胺40 mg/kg×2 d(+3^+4 d)+环孢素(+5^+180 d)+麦考酚钠肠溶片(+5^+35 d)+托珠单抗8 mg/kg×1 d(-1 d)+芦可替尼(-1^+180 d);观察移植效果及aGVHD等不良反应发生情况。结果56例患者均成功植入(100%),中性粒细胞植入中位时间为13 d,血小板植入中位时间为17 d;Ⅱ~Ⅳ度aGVHD发生率为23.2%;Ⅲ~Ⅳ度aGVHD发生率为12.5%。1例患者因aGVHD控制不佳导致死亡;6例患者出现肺部感染;12例患者出现人巨细胞病毒感染或病毒拷贝数持续上升;8例患者出现EB病毒感染或病毒拷贝数持续上升;8例患者出现造血受抑。随访2~16个月,中位随访时间8个月,无复发死亡率(nonrelapse mortality,NRM)为7.2%;总生存率(overall survival,OS)为91.4%。结论单倍型相合移植患者采用PT-Cy联合芦可替尼、托珠单抗方案预防aGVHD的效果较好。细菌、病毒感染率未见明显增加,造血受抑发生率较高,整体耐受性良好。 Objective To evaluate the efficacy of post-transplant cyclophosphamide(PT-Cy)combined with ruxolitinib and tocilizumab in the prevention of acute graft versus host disease(aGVHD)after haploidentical allogeneic peripheral blood hematopoietic stem cell transplantation(HSCT)by a single-arm prospective study.Methods A total of 56 patients undergoing haploidentical allogeneic peripheral blood HSCT in our department from January 1,2019 to March 1,2020 were recruited in this study.The GHVD prevention regiments included:cyclophosphamide 40 mg/kg×2 d(+3^+4 d),ciclosporin 2 mg/kg(+5^+180 d)and mycophenolate sodium enteric-coated tablets 10 mg/kg(+5^+35 d),tocilizumab 8 mg/kg×1 d(-1 d),and ruxolitinib(-1^+180 d).The effect of transplantation and adverse effect of aGVHD were observed.Results The implantation of stem cells was completed successfully among all the 56 patients(100%),with an implantation time of neutrophils of 13 d and of platelets of 17 d.The incidence of gradeⅡ~ⅣaGVHD was 23.2%,and that of gradeⅢ~Ⅳwas 12.5%.One patient died due to poor control of aGVHD,6 patients had pulmonary infection;12 patients had human cytomegalovirus infection or persistent viral copy number rise;8 patients had Epstein-Barr virus infection or persistent viral copy number rise;and 8 patients had hematopoietic suppression.During the follow-up of 2~16 months(median 8 months),nonrelapse mortality(NRM)was 7.2%,and overall survival rate(OS)was 91.4%.Conclusion PT-Cy combined with ruxolitinib and tocilizumab regimen can effectively prevent aGVHD for haplotype concomitant transplantation patients.No significant increases of bacterial and viral infections are observed.This program has a higher incidence of hematopoietic suppression and a good overall tolerance.
作者 白浩成 冯静 王三斌 BAI Haocheng;FENG Jing;WANG Sanbin(Department of Hematology,No.920 Hospital of Joint Logistics Support Force,Kunming,Yunnan Province,650032,China)
出处 《第三军医大学学报》 CAS CSCD 北大核心 2020年第17期1712-1716,共5页 Journal of Third Military Medical University
基金 国家重点研发计划“干细胞及转化研究”重点专项(2017YFA0105502)。
关键词 急性移植物抗宿主病 异基因外周血造血干细胞 单倍型相合 芦可替尼 托珠单抗 acute graft-versus-host disease allogeneic peripheral blood hematopoietic stem cells haplotype congruence ruxolitinib tocilizumab
  • 相关文献

参考文献3

二级参考文献17

  • 1HUANG XJ, LIU DH, LIU KY, et al. Haploidentical hematopoi- eric stem cell transplantation without in vitro T-ceU depletion for the treatment of hematological malignancies [J] Bone Marrow Transplant, 2006,38 (4) : 291-297.
  • 2WANG Y, LIU QF, XU LP, et al. Haploidentical vs identical- sibling transplant for AML in remission: a muhicenter, prospec- tive study [J]. Blood, 2015,125(25) : 3956-3962.
  • 3KANAKRY CG, TSAI HL, BOLANOS-MEADE J, et al. Single- agent GVHD prophylaxis with posttransplantation cyclophos- phamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS [J] Blood, 2014,124(25) :3817-3827.
  • 4BERTAINA A, MERLI P, RUTELLA S, et al. HLA-haploiden- tical stem cell transplantation after removal of ctl3+T and B cells in children with nonmalignant disorders [J]. Blood, 2014,124 (5) : 822-826.
  • 5MO XD, XU LP, LIU DH, et al. Patients receiving HLA-hap- loidentical/partially matched related allo-HSCT can achieve de- sirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT [J]. Bone Marrow Transplant, 2012,47(9) : 1201-1205.
  • 6BARTOLOMEO DP, SANTARONE S, DE ANGELIS G, et al. Haploidentical, unmanipulated, G-CSF primed bone marrow transplantation for patients with high risk hematologic malignan- cies [J]. Blood, 2013,121 (5) :849-857.
  • 7SOLOMON SR, SIZEMORE CA, SANACORE M, et al. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors [Jl. Biol Blood Marrow Transplant, 2015,21 (7) : 1299-1307.
  • 8GROSSO D, GABALLA S, ALPDOGAN O, et al. A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease [J]. Biol Blood Marrow Transplant, 2015, 21 (4) :646-652.
  • 9XU LP, LIU KY, LIU DH, et al. A novel protocol for hap- loidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia [J]. Bone Mar- row Transplant, 2012,47(12) : 1507-1512.
  • 10WANG Z, ZHENG X, YAN H, et al. Good outcome of hap- loidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia [J]. Bone Marrow Transplant, 2014,49(12) : 1481-1485.

共引文献9

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部